{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:29:31Z","timestamp":1794608971962,"version":"4.9.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015537","name":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["324730_192449"],"award-info":[{"award-number":["324730_192449"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006392","name":"Centre Hospitalier Universitaire Vaudois","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jchromb.2023.123917","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:46:38Z","timestamp":1698540398000},"page":"123917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Development and validation of a multiplex HPLC-MS\/MS assay for the monitoring of JAK inhibitors in patient plasma"],"prefix":"10.1016","volume":"1230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-6327","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Tachet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Versace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-927X","authenticated-orcid":false,"given":"Fran\u00e7ois R.","family":"Girardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jchromb.2023.123917_b0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Alexandre","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","article-title":"Rheumatoid arthritis: advances in treatment strategies","volume":"478","author":"Prasad","year":"2023","journal-title":"Mol. Cell. Biochem."},{"issue":"19","key":"10.1016\/j.jchromb.2023.123917_b0025","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jchromb.2023.123917_b0035","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jchromb.2023.123917_b0040","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jchromb.2023.123917_b0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10620-022-07582-w","article-title":"Upadacitinib Is Safe and Effective for Crohn\u2019s Disease: Real-World Data from a Tertiary Center","volume":"68","author":"Traboulsi","year":"2023","journal-title":"Dig. Dis. Sci."},{"issue":"21","key":"10.1016\/j.jchromb.2023.123917_b0050","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jchromb.2023.123917_b0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jchromb.2023.123917_b0060","doi-asserted-by":"crossref","unstructured":"Ponce-Bobadilla AV, Stodtmann S, Eckert D, Zhou W, Liu W, Mohamed MA-O. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. 2022(1179-1926 (Electronic)).","DOI":"10.1007\/s40262-022-01191-6"},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0065","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jchromb.2023.123917_b0080","unstructured":"Pfizer. Summary of product characteristics - Cibinqo. European Medicines Agency (EMA); 2021. Contract No.: EMEA\/H\/C\/005452."},{"key":"10.1016\/j.jchromb.2023.123917_b0085","unstructured":"EEIG BMSP. Summary of product characteristics - Inrebic. European Medicines Agency (EMA); 2021. Report No.: EMEA\/H\/C\/005026 - IAIN\/0009."},{"key":"10.1016\/j.jchromb.2023.123917_b0090","unstructured":"B.V. ELN. Summary of product characteristics - Olumiant. European Medicines Agency (EMA); 2022. Report No.: EMEA\/H\/C\/004085 - II\/0029\/G."},{"key":"10.1016\/j.jchromb.2023.123917_b0095","unstructured":"Europharm N. Summary of product characteristics - Jakavi. European Medicines Agency (EMA); 2022. Report No.: EMEA\/H\/C\/002464 - II\/0053."},{"key":"10.1016\/j.jchromb.2023.123917_b0100","unstructured":"Europe P. Summary of product characteristics - Xeljanz. European Medicines Agency (EMA); 2022. Report No.: EMEA\/H\/C\/004214 - II\/0044."},{"key":"10.1016\/j.jchromb.2023.123917_b0105","unstructured":"AbbVie. Summary of product characteristics - Rinvoq. European Medicines Agency (EMA); 2022. Report No.: EMEA\/H\/C\/004760 - II\/0016."},{"issue":"800","key":"10.1016\/j.jchromb.2023.123917_b0110","first-page":"1979","article-title":"Janus kinase inhibitors : new perspectives for precision medicine ?","volume":"8","author":"Tachet","year":"2022","journal-title":"Rev. Med. Suisse"},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.jchromb.2023.123917_b0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2020.00177","article-title":"The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib","volume":"11","author":"Buclin","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.jchromb.2023.123917_b0130","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1007\/s12325-019-01037-x","article-title":"Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases","volume":"36","author":"Moran","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jchromb.2023.123917_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.733935","article-title":"Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature","volume":"12","author":"Lenoir","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.jchromb.2023.123917_b0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2893.2011.01578.x","article-title":"Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection: Metabolic impact of autoantibodies in HCV","volume":"19","author":"Girardin","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0145","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00280-019-03907-1","article-title":"Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects","volume":"84","author":"Aslanis","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.jchromb.2023.123917_b0150","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.jchromb.2023.123917_b0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","article-title":"Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals","volume":"47","author":"Wang","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0165","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.1980","article-title":"Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites","volume":"62","author":"Wang","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-020-00275-8","article-title":"Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US","volume":"8","author":"Walton","year":"2021","journal-title":"Rheumatol. Therapy."},{"issue":"2","key":"10.1016\/j.jchromb.2023.123917_b0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0163-7258(82)90051-1","article-title":"Kinetics of pharmacologic response","volume":"16","author":"Holford","year":"1982","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2023.123917_b0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.pa.32.040192.001153","article-title":"Population pharmacokinetics\/dynamics","volume":"32","author":"Sheiner","year":"1992","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.jchromb.2023.123917_b0185","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"The Lancet Haematol."},{"key":"10.1016\/j.jchromb.2023.123917_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2019.120450","article-title":"Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure Application to therapeutic drug monitoring","volume":"208","author":"Koller","year":"2020","journal-title":"Talanta."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0195","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000497","article-title":"Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry","volume":"40","author":"Pressiat","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2023.123917_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113968","article-title":"Development and clinical validation of a simple and fast UPLC-ESI-MS\/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring","volume":"197","author":"Llopis","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123917_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2023.115230","article-title":"A high-throughput UHPLC-MS\/MS method for the determination of eight anti-tumor drugs in plasma","volume":"676","author":"Liu","year":"2023","journal-title":"Anal. Biochem."},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0210","doi-asserted-by":"crossref","first-page":"e4458","DOI":"10.1002\/bmc.4458","article-title":"Development and validation of a rapid and sensitive UPLC\u2013MS\/MS assay for the quantification of tofacitinib in human plasma","volume":"33","author":"Bharwad","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2023.123917_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.123076","article-title":"Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS\/MS","volume":"1188","author":"Martens-Lobenhoffer","year":"2022","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.jchromb.2023.123917_b0220","doi-asserted-by":"crossref","first-page":"e3793","DOI":"10.1002\/bmc.3793","article-title":"An LC\u2013MS\/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma","volume":"31","author":"Abdelhameed","year":"2017","journal-title":"Biomed. Chromatogr."},{"issue":"19","key":"10.1016\/j.jchromb.2023.123917_b0225","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4155\/bio-2021-0128","article-title":"Validation of enantioseparation and quantitation of an active metabolite of abrocitinib in human plasma","volume":"13","author":"Tripathy","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2023.123917_b0230","unstructured":"ICH guideline M10 on bioanalytical method validation and study sample analysis, (2022)."},{"issue":"8","key":"10.1016\/j.jchromb.2023.123917_b0235","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpdd.868","article-title":"Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cpdd.899","article-title":"Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis","volume":"10","author":"Vong","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jchromb.2023.123917_b0245","unstructured":"Corporation I. Clinical Pharmacology and Biopharmaceutics review(s) - Jakafi. Food and Drug Administration (FDA); 2011. Report No.: 202192Orig1s000."},{"key":"10.1016\/j.jchromb.2023.123917_b0250","unstructured":"Lilly E. Clinical Pharmacology and Biopharmaceutics review(s) - Olumiant. Food and Drug Administration (FDA); 2017. Report No.: 207924Orig1s000."},{"issue":"5","key":"10.1016\/j.jchromb.2023.123917_b0255","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-021-01104-z","article-title":"Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis","volume":"61","author":"Wojciechowski","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.jchromb.2023.123917_b0260","first-page":"804","article-title":"Dose\/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis. CPT: Pharmacometrics & Systems","volume":"6","author":"Zhang","year":"2017","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0265","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00280-019-03929-9","article-title":"Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia","volume":"84","author":"Ogasawara","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.jchromb.2023.123917_b0270","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jcph.102","article-title":"Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)","volume":"53","author":"Chen","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jchromb.2023.123917_b0275","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40262-017-0605-6","article-title":"Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials","volume":"57","author":"Kl\u00fcnder","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.jchromb.2023.123917_b0280","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-019-00739-3","article-title":"Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials","volume":"58","author":"Kl\u00fcnder","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0285","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcph.1550","article-title":"Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials","volume":"60","author":"Nader","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123917_b0290","unstructured":"Pfizer. Clinical Pharmacology and Biopharmaceutics review(s) - Xeljanz. Food and Drug Administration (FDA); 2011. Report No.: 203214Orig1s000."},{"issue":"2","key":"10.1016\/j.jchromb.2023.123917_b0295","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0003-2670(99)00106-3","article-title":"The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory","volume":"391","author":"Hubert","year":"1999","journal-title":"Anal. Chim. Acta"},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0300","first-page":"169","article-title":"M\u00e9thodes chromatographiques de dosage dans les milieux biologiques : strat\u00e9gie de validation - Rapport d'une commission SFSTP","volume":"7","author":"Chapuzet","year":"1997","journal-title":"STP Pharma Pratiques."},{"key":"10.1016\/j.jchromb.2023.123917_b0305","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","article-title":"UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma","volume":"166","author":"Xu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123917_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.626897","article-title":"Xu R-a. In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC\/MS-MS Method","volume":"11","author":"Tang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0315","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13880209.2022.2048862","article-title":"Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC\u2013MS\/MS assay","volume":"60","author":"Zhang","year":"2022","journal-title":"Pharm. Biol."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0320","first-page":"579","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP proposal\u2014part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.jchromb.2023.123917_b0325","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0731-7085(03)00182-1","article-title":"An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progresses and limitations","volume":"32","author":"Boulanger","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chroma.2007.03.111","article-title":"Analysis of recent pharmaceutical regulatory documents on analytical method validation","volume":"1158","author":"Rozet","year":"2007","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0335","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.chroma.2007.03.102","article-title":"Using tolerance intervals in pre-study validation of analytical methods to predict in-study results: The fit-for-future-purpose concept","volume":"1158","author":"Rozet","year":"2007","journal-title":"J. Chromatogr. A"},{"issue":"6","key":"10.1016\/j.jchromb.2023.123917_b0340","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11095-007-9242-3","article-title":"A Total Error Approach for the Validation of Quantitative Analytical Methods","volume":"24","author":"Hoffman","year":"2007","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jchromb.2023.123917_b0345","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.chroma.2007.02.021","article-title":"Validation of analytical methods based on accuracy profiles","volume":"1158","author":"Feinberg","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123917_b0350","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trac.2018.04.013","article-title":"From method validation to result assessment: Established facts and pending questions","volume":"105","author":"Rudaz","year":"2018","journal-title":"TrAC Trends Anal. Chem."},{"issue":"10","key":"10.1016\/j.jchromb.2023.123917_b0355","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s11095-007-9291-7","article-title":"Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays","volume":"24","author":"Viswanathan","year":"2007","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jchromb.2023.123917_b0360","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00216-004-2791-y","article-title":"New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data","volume":"380","author":"Feinberg","year":"2004","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123917_b0365","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chroma.2014.05.047","article-title":"Derivation of uncertainty functions from validation studies in biological fluids: Application to the analysis of caffeine and its major metabolites in human plasma samples","volume":"1353","author":"Gassner","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123917_b0370","unstructured":"Bioanalytical Method Validation - Guidance for Industry, (2018)."},{"issue":"13","key":"10.1016\/j.jchromb.2023.123917_bib371","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC\u2212MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Analytical Chemistry"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:11:31Z","timestamp":1761606691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223003276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":75,"alternative-id":["S1570023223003276"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123917","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a multiplex HPLC-MS\/MS assay for the monitoring of JAK inhibitors in patient plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123917"}}